「effects」の検索結果

Decompose total effects into direct and indirect paths through mediators using mediation, CMAverse 4-way, HIMA/HIMA2 high-dimensional, BAMA, two-step / MVMR mediation, or double-ML medDML. Use when testing whether a molecular phenotype (expression, methylation, protein) mediates a treatment-outcome relationship, decomposing exposure-mediator interaction via VanderWeele 4-way, screening high-dimensional EWAS mediators, or running MR-based mediation when sequential ignorability is implausible.

日本語の概要は準備中です。原文の説明を表示しています。

Sequence-based deep learning for ATAC-seq using chromBPNet, BPNet, scBasset, or EnFormer. Use when correcting Tn5 bias with neural networks beyond k-mer models, predicting per-base accessibility profiles, scoring in silico variant effects at GWAS or rare-variant SNPs, discovering motifs via DeepLIFT/TF-MoDISco from a trained model, or generating cell-type-specific accessibility predictions for unobserved cell states.

日本語の概要は準備中です。原文の説明を表示しています。

Two-dimensional minimalist style with vibrant colors, clean typography, and no 3D effects for fast, user-friendly interfaces.

日本語の概要は準備中です。原文の説明を表示しています。

Electric neon glow effects with high-contrast color pairings for bold, attention-grabbing interfaces.

日本語の概要は準備中です。原文の説明を表示しています。

Real-world mimicry with textured surfaces, 3D effects, and familiar physical metaphors for intuitive digital interfaces.

日本語の概要は準備中です。原文の説明を表示しています。

Plan explicitly authorized read-only production observations and trace evidence-backed causes into preventive regression coverage without external effects.

日本語の概要は準備中です。原文の説明を表示しています。

Pre-landing PR review. Analyzes diff against the base branch for SQL safety, LLM trust boundary violations, conditional side effects, and other structural issues. Use when asked to "review this PR", "code review", "pre-landing review", or "check my diff". Proactively suggest when the user is about to merge or land code changes. (gstack)

日本語の概要は準備中です。原文の説明を表示しています。

Raw mechanical interfaces fusing Swiss typographic print with military terminal aesthetics. Rigid grids, extreme type scale contrast, utilitarian color, analog degradation effects. For data-heavy dashboards, portfolios, or editorial sites that need to feel like declassified blueprints.

日本語の概要は準備中です。原文の説明を表示しています。

Create handcrafted static SVG graphics and performant SVG animations — icons, illustrations, loaders, path-draw effects, morphing shapes, and motion paths. Load when the user asks to create SVG, draw an SVG icon, animate an SVG, make an SVG loader, path animation, shape morph, animated logo, line drawing effect, or improve trashy AI-generated SVG. Also triggers on "SVG animation", "SMIL", "stroke-dashoffset", "vector illustration", or "self-contained animated SVG".

日本語の概要は準備中です。原文の説明を表示しています。

Build Motion (Framer Motion) React animations — declarative motion components, variants, AnimatePresence, layout transitions, scroll effects, and inline SVG pathLength. Load when the user asks to animate with Motion, Framer Motion, motion.div, AnimatePresence, layout animation, whileInView, or React enter/exit transitions. Also triggers on "framer-motion", "motion/react", "useReducedMotion", or "React animation library". React/Next only — not README embeds or non-React.

日本語の概要は準備中です。原文の説明を表示しています。

Build GSAP JavaScript animations for web apps — timelines, scroll-driven motion, SVG draw/morph/path effects, and React integration with useGSAP. Load when the user asks to animate with GSAP, add ScrollTrigger, draw SVG paths with GSAP, morph SVG shapes, sequence page animations, or wire GSAP in React/Next/Vue. Also triggers on "GSAP timeline", "DrawSVG", "MotionPath", "gsap.context", or "scroll animation library". Not for self-contained README/GitHub SVG files.

日本語の概要は準備中です。原文の説明を表示しています。

Pick the right business-model canvas (Lean Canvas, Business Model Canvas, or Value Proposition Canvas) for the stage and fill it with specifics — one segment, one primary canvas, top-3 assumptions, no fluff in the moat or channel boxes. Load when the user asks to fill a business model canvas, lean canvas, value proposition canvas, model this business, map the business model, says "fill the BMC", "make a Lean Canvas", "Value Proposition Canvas for this", "model this idea", "what's the business model", "design the business model". Sub-skill of `venture-exploration`. Hard-bans "everyone" segments, generic channels ("SEO/social/content/ads"), and "unfair advantage = AI/data/network effects" with no concrete asset. Does NOT score viability — for that use `idea-evaluation`.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze spatial cell-cell interactions, neighborhoods, and niches in IMC/MIBI data with squidpy and imcRtools, covering neighborhood-enrichment permutation nulls, the abundance-vs-density confound, inhomogeneous Ripley's K, cellular-neighborhood discovery, graph-construction (contact vs proximity), and edge effects. Use when testing whether cell types co-locate, choosing a spatial null, building a neighbor graph, discovering tissue niches, or deciding whether a spatial pattern is real or a density/segmentation artifact.

日本語の概要は準備中です。原文の説明を表示しています。

Quality control for IMC/MIBI data across pixel, channel, image, slide, and batch levels, covering Poisson-count SNR (cell-level Gaussian-mixture and empty-channel comparison), spillover-matrix QC (the three physical sources), drift and the missing EQ-bead analog, acquisition artifacts, and sample-of-origin batch effects. Use when deciding whether to keep or drop a channel, ROI, or slide, distinguishing a dim antibody from a failed one, reading a spillover matrix, or diagnosing batch-driven clustering before analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.

日本語の概要は準備中です。原文の説明を表示しています。

Handles batch effects in bulk RNA-seq via design-matrix inclusion (the correct path for DE), ComBat/ComBat-seq for visualization, SVA for unknown latent factors, RUVSeq for negative-control-gene-anchored unwanted variation, and limma::removeBatchEffect for plotting only. Encodes the Nygaard 2016 cardinal sin against testing on a batch-corrected matrix, the choice between SVA/RUVg/RUVs/RUVr, the confounding non-identifiability problem, the single-cell boundary (Harmony/MNN are NOT for bulk), and the Goh 2017 harmonization critique. Use when designing a DE analysis with batch structure, troubleshooting batch-dominated PCA, choosing ComBat vs ComBat-seq, handling unknown batch via SVA, integrating across studies, or deciding when (rarely) to subtract batch.

日本語の概要は準備中です。原文の説明を表示しています。

Build forest plots (HR, OR, RR, beta-coefficient summaries with CIs) and funnel plots (meta-analysis publication-bias diagnostics) using forestplot, metafor, ggforest, and MendelianRandomization with proper axis-scaling, summary-diamond placement, subgroup nesting, and Egger / trim-and-fill asymmetry tests. Use when summarizing effects across subgroups, trials, or instruments — meta-analysis, Mendelian randomization, subgroup HRs.

日本語の概要は準備中です。原文の説明を表示しています。

Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.

日本語の概要は準備中です。原文の説明を表示しています。

Predict RBP binding from RNA sequence using deep learning models (RBPNet sequence-to-signal, RNAProt RNN, GraphProt2 GCN with structure, DeepCLIP, DeepRiPe multi-modal CNN) for variant-effect prediction, in silico binding-site discovery, model interpretation, and transfer learning from CLIP and RBNS datasets. Use when computational prediction of RBP binding from sequence is needed, evaluating variant effects on binding without further wet-lab experiments, comparing model performance, or training a custom model on ENCODE eCLIP data.

日本語の概要は準備中です。原文の説明を表示しています。

Decompose total effects into direct and indirect paths through mediators using mediation, CMAverse 4-way, HIMA/HIMA2 high-dimensional, BAMA, two-step / MVMR mediation, or double-ML medDML. Use when testing whether a molecular phenotype (expression, methylation, protein) mediates a treatment-outcome relationship, decomposing exposure-mediator interaction via VanderWeele 4-way, screening high-dimensional EWAS mediators, or running MR-based mediation when sequential ignorability is implausible.

日本語の概要は準備中です。原文の説明を表示しています。

Fits structural equation models to GWAS summary statistics using GenomicSEM (Grotzinger 2019), including common-factor models, confirmatory factor models, ESEM, common-factor GWAS with Q_SNP heterogeneity, multivariate Wald tests, and stratified GenomicSEM partitioned heritability. Reconciles results against MTAG multi-trait analysis. Handles sample overlap via the LDSC sampling-covariance matrix, identifies and resolves Heywood cases, and verifies model fit with CFI / RMSEA. Use when modeling latent genetic architecture across correlated traits, running multivariate GWAS on a shared factor, distinguishing factor-mediated from trait-specific SNP effects, or comparing GenomicSEM common-factor results against MTAG when both depend on accurate sampling covariance.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Trains and applies base-resolution deep learning models on ChIP-seq / ChIP-nexus / CUT&RUN data. Uses BPNet (Avsec 2021 Nat Genet 53:354; soft motif syntax from ChIP-nexus), chromBPNet (Pampari A et al 2025 Nat Genet; bias-factorized base-resolution profiles), EnFormer (Avsec 2021 Nat Methods 18:1196; 196 kb input, ~100 kb effective receptive field), DeepSEA (Zhou 2015; multi-task CNN), and JASPAR 2026 deep-learning collection (1259 BPNet ChIP models). Performs in silico mutagenesis for variant-effect prediction, DeepLIFT/Grad attribution, and TF-MoDISco motif discovery from attribution scores. Use when predicting variant effects on TF binding, discovering soft motif syntax / cooperativity, integrating ChIP-seq with sequence-only predictions, or applying precomputed JASPAR Deep Learning models to new variants.

日本語の概要は準備中です。原文の説明を表示しています。